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Oral anticoagulants have been used in patients with vascular disease for over 40 years, yet their
role in the secondary prevention of recurrent cardiovascular (CV) events remains controver-
sial. The objectives of this systematic review are to more reliably determine the role of oral
anticoagulants with and without antiplatelet therapy in patients with established coronary
artery disease (CAD). Randomized trials in which oral anticoagulants were tested in CAD
patients who were treated for at least three months were identified, and each trial was
classified by the targeted level of intensity of anticoagulation. Data from the trials were
combined using the modified Mantel-Haenszel method, and odds ratios were computed.
Data from over 20,000 patients indicated that high-intensity oral anticoagulation (interna-
tional normalized ratio [INR] 2.8) significantly reduced CV complications and increased
bleeding compared with controls. Moderate-intensity oral anticoagulation (INR 2 to 3) also
reduced CV complications compared with controls. The combination of moderate-intensity
oral anticoagulation and aspirin is more effective and equally as safe as aspirin alone.
Low-intensity oral anticoagulation (INR 2) in the presence of aspirin does not reduce CV
complications and increases bleeding compared with aspirin alone. (J Am Coll Cardiol
2003;41:62S–69S) © 2003 by the American College of Cardiology Foundation
Oral anticoagulation (OA) has been used in patients with
vascular disease for more than 40 years, yet its role is still
controversial (1–3). This is because randomized trials have
produced conflicting results, some showing a clear benefit,
and some showing no benefit and increased harm. Further-
more, OA is inconvenient to use because it requires careful
monitoring and dose adjustment to prevent over-
anticoagulation. This contrasts with antiplatelet agents,
which are easier to administer, have been clearly proven to
reduce cardiovascular (CV) complications in patients with
established vascular disease (4), and are relatively safe.
In order to more reliably determine the role of OA with
and without antiplatelet therapy, we recently conducted an
overview of all available trials that tested OA in patients
with established coronary artery disease (CAD) (3). All
trials were stratified by the targeted level of intensity of
anticoagulation and by aspirin use. In this initial review
there was strong evidence that high-intensity OA (interna-
tional normalized ratio [INR] 2.8) reduced CV compli-
cations and low-intensity OA (INR 2.0) did not. How-
ever, few data existed to produce reliable results for the
effects of moderate-intensity OA (INR 2 to 3), with or
without aspirin use. Since this original publication, six
randomized clinical trials that tested moderate-intensity
OA in CAD patients have been completed (5–11). In this
article, the results of these recent trials are presented, and
the role of moderate-intensity OA in CAD patients is
clarified.
The original overview included all randomized studies
that were published between 1960 and July 1999, recruited
patients with established CAD, and continued OA treat-
ment for at least three months. For this update, data for
published and unpublished randomized trials that met these
same criteria are included. Each trial was classified by the
targeted intensity of OA, using methods previously de-
scribed (3). Considering the variable outcomes reported
across the recently completed trials, for this review, the
primary efficacy outcome is the composite of CV death,
myocardial infarction (MI), and stroke, and the primary
safety outcome is major bleeding. The events were counted
as they were defined in the individual trials. In general, the
definitions of the primary outcome events were similar.
Major bleeding events were defined by most trials as
bleeding episodes that required blood transfusion or surgical
intervention.
The statistical method used to combine data from indi-
vidual trials is the modified Mantel-Haenszel method (11).
This method has been used extensively in the previous
meta-analyses (3,4). The odds ratio (OR) (and its 95%
confidence interval [CI]) is calculated for each trial. The
odds reduction (ORed) is calculated using 1 minus the OR
and is expressed as a percent.
The six additional trials involved 14,587 patients (5–10).
Three of these trials compared three treatments: moderate-
intensity OA plus aspirin, moderate-high-intensity OA
alone, and aspirin alone (8–10). The other three trials
compared moderate-intensity OA and aspirin to aspirin
alone (5–7). The characteristics of the six new trials are
Please refer to the Trial Appendix at the back of this supplement for the complete list
of clinical trials.
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found in Table 1, and their results are summarized in the
following text.
ASPECT II. The Antithrombotics in the Secondary Pre-
vention of Events in Coronary Thrombosis (ASPECT)-II
trial was a multicenter open trial involving 53 sites random-
izing 993 patients who had suffered an acute coronary
syndrome (ACS) (9). Patients were randomly assigned
within eight weeks of hospital discharge to receive com-
bined moderate-intensity OA (target INR 2 to 2.5) and
low-dose aspirin (80 mg/day) (n 333), high-intensity OA
(target INR 3 to 4) (n  330), or low-dose aspirin (80
mg/day) (n  336). Patients were followed up for a
maximum of 26 months (median of 12 months). The
primary outcome was the first occurrence of MI, stroke, or
death. A significant 50% risk reduction was observed when
the combination OA and aspirin (4.8%) was compared with
aspirin alone (9.2%; p  0.05). Also a significant 45% risk
reduction was observed when OA (5.2%) was compared
with aspirin alone (9.2%; p  0.05) (9). Although the
composite outcome was lower in the combination group
than in the OA-alone group, this difference was not
significant. Significantly more major bleeding episodes were
observed among patients receiving the combination of OA
and aspirin (2.1%) than among those receiving OA alone
(0.9%) or aspirin alone (0.9%). Therefore, in patients who
were hospitalized with an ACS, aspirin combined with OA
at either moderate or high intensity is more effective than
aspirin alone in reducing subsequent CV events.
BAAS. A total of 1,058 patients were randomized in the
Balloon Angioplasty and Anticoagulation Study (BAAS)
(6). Of these, 530 patients were randomly assigned to
warfarin (INR 2.1 to 4.8) plus aspirin (100 mg/day), and
528 patients were randomized to receive aspirin alone (100
mg/day). Patients were pre-treated with warfarin (median of
6 days before percutaneous coronary intervention) and
aspirin before angioplasty. The mean INR before angio-
plasty was 2.7 1.1, and during follow-up it was 3.0 1.1.
At 30 days, the composite end point of death, MI, target
revascularization, and stroke occurred in 3.4% patients
treated with warfarin plus aspirin, compared with 6.4% of
patients treated with aspirin alone, which is associated with
a relative risk reduction of 47% (95% CI, 8% to 70%; p 
0.04). At one year, the event rate was 14.3% in the
combination group vs. 20.3% in the aspirin-alone group, for
a relative risk reduction of 29% (95% CI, 7% to 46%). The
incidence of major bleeding during hospitalization was 3.2%
in the combination group versus 1.0% in the aspirin-alone
group. In this study, therefore, warfarin combined with
aspirin, begun before angioplasty and continued for at least
six months, appears to be more effective than aspirin alone
in the prevention of acute and late complications after
coronary angioplasty.
CHAMP. The Combination Hemotherapy And Mortality
Prevention (CHAMP) study was a randomized, open-
labelled trial comparing warfarin (target INR 1.5 to 2.5)
combined with aspirin (81 mg/day) to aspirin monotherapy
(162 mg/day) in patients after acute MI. Within 14 days of
MI, 5,059 patients were enrolled and followed for a median
of 2.7 years (7). The primary outcome was total mortality.
This occurred in 17.6% of the patients randomized to OA
and aspirin versus 17.3% of patients randomized to aspirin
alone (p  0.76). Recurrent MI occurred in 13.3% of
patients receiving OA and aspirin versus 13.1% receiving
aspirin alone (p 0.78). Stroke occurred in 3.1% of patients
receiving OA and aspirin versus 3.5% receiving aspirin, (p
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
CAD  coronary artery disease
CV  cardiovascular
INR  international normalized ratio
MI  myocardial infarction
OA  oral anticoagulation
ORed  odds reduction
Table 1. Characteristics of Recent Trials
Trial Population
Randomized
Comparisons Management
Achieved
INR
Compliance
End of Study
Duration
of Study
ASPECT-2 (9) ACS OA (2–2.5)  A (80 mg) n  332 2.4 77% Max 26 months
OA (3–4.0) n  325 3.2 80%
A (80 mg) n  336 87%
BAAS (6) Angioplasty OA (2.1–4.8)  A (100 mg) n  530 3.0 NA 12 months
A (100 mg) n  528
CHAMP (7) AMI OA (1.5–2.5)  A (81 mg) n  2,522 1.8 71% 2.7 years
A (162 mg) n  2,537
Huynh et al. (8) ACS prior CABG OA (2–2.5)  A (80 mg) n  44 NA 86% 12 months
OA (2–2.5) n  45
A (80 mg) n  46
OASIS (5) ACS OA (2–2.5)  A (325 mg) n  1,848 2.1 64% 5 months
A (325 mg) n  1,864
WARIS-2 (10) AMI OA (1.5–2.5)  A (75 mg) n  1,208 2.2 NA 4 years
OA (2.8–4.2) n  1,216 2.8
A (160 mg) n  1,206
A  aspirin; ACS  acute coronary syndromes; AMI  acute myocardial infarction; CABG  coronary artery bypass graft; INR  international normalization ratio; NA 
not available; OA  oral anticoagulants. Trials are defined in appendix of this supplement.
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0.52). No significant differences in the composite of CV
death, stroke, and MI were observed. Major bleeding
occurred more frequently with combination therapy versus
aspirin, with 1.28 versus 0.72 events per 100 persons per
year (p  0.001). The mean INR achieved in the antico-
agulant group was 1.8. By the end of the trial, 30% of
patients had discontinued OA therapy.
Huynh et al. (8). This study, undertaken by Huynh et al.
(8), was a double-blind, randomized trial of patients with a
non-ST-segment elevation ACS who had undergone pre-
vious coronary artery bypass graft surgery. The duration of
treatment was 12 months. Patients (n  135) with this
condition were randomized to receive either warfarin plus
aspirin (target INR 2 to 2.5) (n  44), warfarin alone (n 
45), or aspirin alone (n 46). The primary outcome was the
composite of any death, MI, or unstable angina requiring
hospitalization. This occurred in 11.3% randomized to
combination therapy, 14.6% in the OA-alone group, and
11.5% in the aspirin-alone group (overall p  0.76). This
trial was stopped early due to poor recruitment and was
underpowered to show a statistical difference between the
treatment groups.
OASIS-II. In the Organization to Assess Strategies for
Ischemic Syndromes-II study, 3,712 subjects with ACS
were randomized within 12 to 48 h of receiving intravenous
antithrombotic treatment to receive OA therapy (n 
1,848) or standard therapy (n  1,864) (5). All patients
were encouraged to take aspirin (mean 325 mg/day). Pa-
tients were followed-up for five months after entry into the
study. Of the patients in the combination group, 7.6%
suffered CV death, MI, or stroke, versus 8.3% of the
patients in the standard therapy group, for a relative risk
reduction of 10% (95% CI, 14% to 28%; p 0.40). Overall,
there was an excess of major bleeding (2.7% vs. 1.3%)
experienced in the combination group compared with the
aspirin-alone group (p  0.004). The mean INR among
patients receiving OA was 2.1 0.9, and compliance to OA
was 64% at the end of the trial. A retrospective subgroup
analysis indicated that among countries with good compli-
ance, there was an apparent benefit (risk reduction of 32;
95% CI, 5 to 52), compared with no benefit in countries
with poor compliance (relative risk, 1.17; 95% CI, 0.86 to
1.60).
WARIS-II. The Warfarin-Aspirin ReInfarction-II Study
(WARIS-II) was a randomized open-label trial. Over 3,600
patients with acute MI from 20 hospitals in Norway were
assigned to one of three treatment arms, which included
warfarin (INR 2 to 2.5) plus aspirin 75 mg/day (n  1208),
warfarin (INR 2.8 to 4.2; n  1216), or aspirin 160 mg/day
(n  1206) (10). Patients were enrolled between January
1994 and June 1998 and monitored for four years. The
average age of the patients was 60 years, and 77% were men.
In addition, about half of these patients received thrombo-
lytic therapy as treatment for their acute MI. The primary
end point of the study was the combination of death,
recurrent MI, or stroke. Treatment with OA (mean INR
2.2) plus aspirin compared with aspirin alone reduced CV
death, MI, and stroke by 29% (95% CI, 14 to 42; p 
0.0005). Oral anticoagulation alone (mean INR  2.8)
compared with aspirin reduced CV death, MI, and stroke by
19% (95% CI, 1 to 33; p  0.028). Major bleeding was
significantly increased in patients treated with OA and
Figure 1. High intensity oral anticoagulation versus control. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT 
Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; CI  confidence interval; df  degrees of freedom; N  study
population; n  subset population; OA  oral anticoagulation; OR  odds ratio; WARIS  Warfarin-Aspirin ReInfarction Study.
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aspirin (0.58% per year) and OA alone (0.52% per year),
compared with patients who received aspirin alone (0.15%
per year).
High-intensity OA (INR >2.8) versus control. Data
from 13 trials (12–24) involving 8,140 patients were avail-
able to compare high-intensity OA to control. Cardiovas-
cular death, MI, or stroke occurred in 20.3% of patients
treated with OA, versus 30.3% of patients who received no
therapy, translating into an ORed of 43% (95% CI, 37 to
49; p  0.0001) (Fig. 1). Among 11 trials involving 7,933
patients (12–16,18,19,21–25), major bleeding occurred in
4.6% of OA patients versus 0.7% of control patients, for an
odds increase of 4.5 (95% CI, 2.5 to 6.0; p 0.00001) (Fig.
2).
Moderate-intensity OA (INR 2 to 3) versus control.
Data from three trials are available (26–28). A non-
significant 16% (95% CI,11 to 37; p 0.20) reduction in
CV death, MI, and stroke was observed among patients
receiving OA versus controls (Fig. 3). Major bleeding
occurred in 3.5% of the patients receiving OA, versus no
patients in the control groups, for an odds increase of 7.67
(95% CI, 3.3 to 18; p  0.0001) (Fig. 2).
Moderate- or high-intensity OA versus aspirin. Data
from six trials and 4,155 patients in which OA and aspirin
Figure 2. Major bleeding rates in patients with vascular disease. A  aspirin; C  control; INR  international normalized ratio; N  study population;
n  subset population; OA  oral anticoagulation. (Adapted from Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease:
a meta-analysis. JAMA 1999;282:2058–67. Copyrighted 2002, American Medical Association.)
Figure 3. Moderate intensity oral anticoagulation versus control. Outcomes are cardiovascular death, myocardial infarction, or stroke. CI  confidence
interval; COOP  Veterans Administration COOPerative study; df  degrees of freedom; OA  oral anticoagulation; N  study population; n  subset
population; OR  odds ratio.
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were directly compared were available to evaluate the
outcome of death, MI, or stroke (9,10,24,26,29,30). This
outcome occurred in 13.5% of patients receiving OA, versus
16.3% among patients receiving aspirin alone, resulting in
an ORed of 21% (95% CI, 6 to 33; p  0.008) (Fig. 4). In
an analysis of data from 10 trials involving 6,655 patients
(8–10,24,26,30–33), major bleeding was found to increase
2.1-fold (95% CI, 1.7 to 2.1; p  0.00001) among patients
receiving OA (Fig. 2).
Moderate-to-high-intensity OA plus aspirin versus aspi-
rin alone. Data were available from seven trials
(5,7,9,10,34–36) involving 12,333 patients for assessing the
combined outcome of CV death, MI, or stroke. This
outcome occurred in 15.9% of patients who received OA
plus aspirin, versus 12.6% who received aspirin alone,
resulting in a significant 12% ORed (95% CI, 3 to 20; p 
0.01) (Fig. 5). Another analysis of data from nine trials
involving 13,498 patients (5–10,34–36) found that major
bleeding occurred in 3.0% of patients receiving the combi-
nation, versus 1.7% of patients receiving aspirin only, for a
relative increase of 1.74 (95% CI, 1.39 to 2.17; p  0.10)
(Fig. 2).
Moderate-to-high-intensity OA and aspirin versus OA
alone. Data from three trials involving 3,142 patients were
available to compare the occurrence of CV death, MI, and
stroke (9,10,34). These events occurred in 12.5% of subjects
receiving the combination therapy versus 14.3% of people
receiving OA alone. A modest reduction of 14% in favor of
OA and aspirin compared with OA alone was observed
(95% CI, 6% to 30%; p  0.15) (Fig. 6). In four trials
Figure 4. Moderate-to-high-intensity oral anticoagulation versus aspirin. Outcomes are cardiovascular death, myocardial infarction, or stroke. ASPECT
 Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS  Antithrombotic Therapy in Acute Coronary Syndrome;
CI  confidence interval; df  degrees of freedom; EPSIM  Enquete de Prevention Secondaire de I’Infarctus du Myocarde; N  study population; n 
subset population; OR  odds ratio; WARIS  Warfarin-Aspirin ReInfarction Study.
Figure 5. Moderate-to-high-intensity oral anticoagulation plus aspirin versus aspirin alone. Outcomes are cardiovascular death, myocardial infarction, or
stroke. ASPECT  Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS  Antithrombotic Therapy in Acute
Coronary Syndrome; CHAMP  Combination Hemotherapy And Mortality Prevention; CI  confidence interval; df  degrees of freedom; OA  oral
anticoagulation; OASISOrganization to Assess Strategies for Ischemic Syndromes; OR odds ratio; WARISWarfarin-Aspirin ReInfarction Study.
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involving 3,231 patients (8,9,10,34), no substantial differ-
ence in major bleeding episodes was observed between the
combination therapy (2.2%) and OA alone (2.3%) (OR,
0.95; 95% CI, 0.60 to 1.51; p  0.80) (Fig. 2).
Low-intensity OA (INR <2.0). Three trials (35,37,38)
(n  8,435) compared low-intensity OA plus aspirin to
aspirin alone. The Coumadin Aspirin Reinfarction Study
(CARS) trial design included three arms that compared
fixed-dose 1 mg warfarin plus aspirin with fixed-dose 3 mg
warfarin plus aspirin, and with aspirin alone. The INR
values in the 1 mg OA group increased minimally; there-
fore, data for only the 3-mg arm were used for comparison
with the aspirin-alone arm (37). No significant benefit was
observed in favor of OA and aspirin versus aspirin alone for
the combination of CV death, MI, and stroke (OR, 0.91;
95% CI, 0.79 to 1.06; p  0.10). This outcome occurred in
8.8% of patients who received combination therapy, versus
9.6% who received aspirin (Fig. 7). Major bleeding occurred
in 2.3% of the patients receiving combination therapy versus
1.8% of the patients who received aspirin, resulting in a
non-significant 25% increase in bleeding (Fig. 2).
Discussion, implications, and conclusions. This meta-
analysis of randomized trials includes data from more than
20,000 patients with established CAD. Clear reductions in
total mortality, MI, and stroke occurred among patients
treated with OA at high intensity (INR 2.8 to 4.8),
although this therapy was also associated with a significant
increase in major bleeding. Conversely, low-intensity OA
(INR 2.0) in the presence of aspirin does not confer any
benefit over aspirin alone but still increases major bleeding
episodes. Moderate-intensity OA reduced recurrent isch-
emic events by 16% compared with controls. For moderate-
or high-intensity OA, the reduction in CV events was 21%
compared with aspirin, and when used together with aspi-
rin, moderate-to-high-intensity OA reduced recurrent isch-
emic events by 12% compared with aspirin alone. A com-
parison of moderate- or high-intensity OA alone versus the
combination of moderate-intensity OA plus aspirin may be
more effective than moderate-to-high-intensity OA alone,
although with the paucity of current data, this cannot be
confirmed. Certainly there is no apparent significant in-
crease in bleeding with the combination of moderate-
Figure 6. Moderate intensity oral anticoagulation plus aspirin versus moderate-to-high-intensity oral anticoagulation. Outcomes are cardiovascular death,
myocardial infarction, or stroke. ASPECT Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis; ATACS Antithrombotic
Therapy in Acute Coronary Syndrome; CI  confidence interval; df  degrees of freedom; OA  oral anticoagulation; OR  odds ratio; WARIS 
Warfarin-Aspirin ReInfarction Study.
Figure 7. Low intensity oral anticoagulation plus aspirin versus aspirin alone. Outcomes are cardiovascular death, myocardial infarction, or stroke.
CABG  coronary artery bypass graft; CARS  Coumadin Aspirin Reinfarction Study; CI  confidence interval; df  degrees of freedom; N  study
population; n  subset population; OA  oral anticoagulation; OASIS  Organization to Assess Strategies for Ischemic Syndrome; OR  odds ratio.
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intensity OA and aspirin compared with OA alone. This
supports other evidence that it is the INR intensity rather
than the simultaneous use of antiplatelet agents with OA
that leads to bleeding episodes and justifies careful moni-
toring of the INR for patients who are receiving OA (39).
The data presented in this overview represent the observed
treatment effects because the summary estimates included
all patients whether they were actually compliant with the
intended therapy or not. Therefore, these estimates are
conservative, represent an intention-to-treat analysis, and
are likely to be an underestimate of the true risk reduction
achievable with OA when compliance is maximized and the
target INR is achieved. An example of the effect of
non-compliance on the overall estimate of treatment effect
comes from the OASIS-2 trial (5). In this trial, OA and
aspirin versus aspirin alone was associated with a small
non-significant reduction in CV death, MI, and stroke
(7.6% vs. 8.3%; risk reduction, 0.90; 95% CI, 0.72 to 1.14;
p  0.40) (5). However, at the end of the follow-up period,
only 63.7% of patients who had been randomized to receive
OA and aspirin were actually receiving their OA. Compli-
ance with OA varied significantly between the 14 countries
participating in the trial. The “good compliance” countries
were those in which compliance with OA was at least 70%
at 35 days; “poor compliance” countries had 70% at 35
days. In the “good compliance” countries, the combination
of OA and aspirin was associated with a significant 32%
reduction in CV death, MI, and stroke (6.1% vs. 8.9%; risk
reduction, 0.68; 95% CI, 0.48 to 0.95; p  0.02) compared
with aspirin alone. Conversely, in “poor compliance” coun-
tries, no reduction in the composite outcome of CV death,
MI or stroke was observed. As expected, there was a larger
relative increase in major bleeding among the “good com-
pliance” countries compared with the “poor compliance”
countries (2.71 vs. 1.58). Therefore, in the high compliance
subgroup, OA and aspirin use was associated with a relative
risk reduction three times that observed with OA and
aspirin using the intent-to-treat approach.
This review provides evidence that among CAD patients
the combination of moderate-intensity OA plus aspirin is
more effective than aspirin alone and is relatively safe. This
combination should be considered for high-risk patients
with CAD, including those who suffer a CV event while
receiving aspirin monotherapy (e.g., an aspirin failure). The
potential benefits of OA therapy in reducing serious clinical
events such as MI, stroke, and death should be weighed
against the risk that OA might cause life-threatening
bleeding. Clinical algorithms can assist clinicians in making
such judgments. Recently, dual antiplatelet therapy has been
shown to be superior to aspirin alone in preventing recurrent
MI, stroke, and CV death among patients with ACS (40).
The efficacy and safety profiles comparing dual antiplatelet
therapy with moderate-intensity OA and aspirin have not
been adequately evaluated, and future studies should address
this question.
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